Adverse clinical outcomes associated with RAAS inhibitor discontinuation: analysis of over 400 000 patients from the UK Clinical Practice Research Datalink (CPRD)
Publication: Clinical Kidney Journal
Toby J L Humphrey, Glen James, Eric T Wittbrodt, Donna Zarzuela, Thomas F Hiemstra
30 January 2021
Summary:
In an observational study analysing data from over 430,000 patients, those who had their RAASi – blood pressure medications – interrupted or stopped, were found to have worse outcomes than those who continued with their treatment.
The patients who had medication interruptions or discontinuated were more likely to be hospitalised, to have a cardiac arrest or develop kidney damage than those who continued on their RAASi medications throughout the study.
This study highlights that the potential risks for and against RAASi treatment interruption or discontinuation be very carefully considered in patients for whom guideline-recommended RAAS inhibitor therapy is indicated.
